Gonzales-Chambers R, Rosenfeld C, Winkelstein A, Dameshek L
Department of Internal Medicine, University of Pittsburgh, School of Medicine, Pennsylvania.
Am J Hematol. 1991 Feb;36(2):157-9. doi: 10.1002/ajh.2830360219.
A therapeutic trial of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) was attempted in a patient with neutropenia and frequent infections secondary to T-gamma lymphoproliferative disease (T-gamma LPD). During the 14 days of subcutaneous rhGM-CSF (500 micrograms/m2/day), the absolute eosinophil count increased from 0 to 9,455/microliters. By contrast, the absolute neutrophil count decreased. Toxicity related to rhGM-CSF included arthralgia and nonspecific chest pain. The possible mechanism for the rhGM-CSF induced selective eosinophilia is discussed.
对一名因Tγ淋巴细胞增殖性疾病（TγLPD）继发中性粒细胞减少和频繁感染的患者进行了重组人粒细胞-巨噬细胞集落刺激因子（rhGM-CSF）的治疗试验。在皮下注射rhGM-CSF（500微克/平方米/天）的14天期间，绝对嗜酸性粒细胞计数从0增加到9455/微升。相比之下，绝对中性粒细胞计数下降。与rhGM-CSF相关的毒性包括关节痛和非特异性胸痛。讨论了rhGM-CSF诱导选择性嗜酸性粒细胞增多的可能机制。
